Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues

Executive Summary

Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.

Related Content

EMA Restricts Sanofi's Lemtrada Use, Initiates Risk-Benefit Review
Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator
EMA Calls For Zinbryta's ‘Immediate’ Suspension After More Reports of Brain Disorders
Roche's Ocrevus: A Rare First-Year Blockbuster
New EU Restrictions On Biogen’s MS Drug Zinbryta Are ‘Damaging’, Analyst Warns
Hepatic Safety Of Biogen Idec’s Zinbryta Under Close Scrutiny In EU
Race To Build Zinbryta's MS Market Share Ahead Of Even More Competition
Biogen/AbbVie MS Drug Zinbryta Approved; Faces Crowded Market, Liver Concerns
Biogen's Zinbryta Gets EU Nod – But Where Will It Fit In?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts